S
Stefan Kopf
Researcher at University Hospital Heidelberg
Publications - 95
Citations - 2314
Stefan Kopf is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 19, co-authored 62 publications receiving 1558 citations. Previous affiliations of Stefan Kopf include Heidelberg University.
Papers
More filters
Journal ArticleDOI
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.
Khurrum Shahzad,Khurrum Shahzad,Fabian Bock,Fabian Bock,Wei Dong,Hongjie Wang,Hongjie Wang,Stefan Kopf,Shrey Kohli,Moh'd Mohanad Al-Dabet,Satish Ranjan,Juliane Wolter,Christian Wacker,Ronald Biemann,Stoyan Stoyanov,Klaus G. Reymann,Peter Söderkvist,Olaf Groß,Vedat Schwenger,Sascha Pahernik,Peter P. Nawroth,Herman Josef Gröne,Thati Madhusudhan,Berend Isermann +23 more
TL;DR: Mitochondrial reactive oxygen species (ROS) and Nlrp3-inflammasome activation in non-myeloid-derived cells aggravate diabetic nephropathy, and targeting the inflammasomes may be a potential therapeutic approach to diabetic neophropathy.
Journal ArticleDOI
Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.
Oana P. Zaharia,Klaus Strassburger,Alexander Strom,Gidon J. Bönhof,Yanislava Karusheva,Sofia Antoniou,Kálmán Bódis,D Markgraf,Volker Burkart,Karsten Müssig,Jong-Hee Hwang,Olof Asplund,Leif Groop,Emma Ahlqvist,Jochen Seissler,Peter P. Nawroth,Stefan Kopf,Sebastian M. Schmid,Michael Stumvoll,Andreas Pfeiffer,Stefan Kabisch,Sergey Tselmin,Hans U. Häring,Dan Ziegler,Oliver Kuss,Julia Szendroedi,Michael Roden,Bengt-Frederik Belgardt,Anette E. Buyken,Jürgen Eckel,Gerd Geerling,Hadi Al-Hasani,Christian Herder,Andrea Icks,Jorg Kotzka,Eckart Lammert,Daniel F. Markgraf,Wolfgang Rathmann +37 more
TL;DR: In patients with newly diagnosed type 1 or type 2 diabetes, hepatocellular lipid content was highest at baseline in patients assigned to the SIRD cluster and insulin resistance index at baseline was highest in patients with SIRD and MOD.
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic
Fabian Bock,Wei Dong,Hongjie Wang,Stefan Kopf,Shrey Kohli,Satish Ranjan,Juliane Wolter,Christian Wacker,Ronald Biemann,Stoyan Stoyanov,Klaus G. Reymann,Olaf Gro,Vedat Schwenger,Sascha Pahernik,Peter P. Nawroth,Thati Madhusudhan,Berend Isermann +16 more
TL;DR: In this paper, an association of diabetic nephropathy with inflammasome activation has been shown, but the pathophysiological relevance of this finding remains unknown, and specific therapies targeting sterile inflammation in diabetic neephropathy are lacking.
Journal ArticleDOI
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Sabine Kahl,Sofiya Gancheva,Klaus Straßburger,Christian Herder,Jürgen Machann,Hisayuki Katsuyama,Stefan Kabisch,Elena Henkel,Stefan Kopf,Merit Lagerpusch,Konstantinos Kantartzis,Yuliya Kupriyanova,Daniel F. Markgraf,Theresa van Gemert,Birgit Knebel,Martin Wolkersdorfer,Oliver Kuss,Jong-Hee Hwang,Stefan R. Bornstein,Christian Kasperk,Norbert Stefan,Andreas Pfeiffer,Andreas L. Birkenfeld,Michael Roden +23 more
TL;DR: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration, and Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity.
Journal ArticleDOI
Sustained Effects of a Mindfulness-Based Stress-Reduction Intervention in Type 2 Diabetic Patients: Design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-Study)
Mechthild Hartmann,Stefan Kopf,Claudia Kircher,Verena Faude-Lang,Zdenka Djuric,Florian Augstein,Hans-Christoph Friederich,Meinhard Kieser,Angelika Bierhaus,Per M. Humpert,Wolfgang Herzog,Peter P. Nawroth +11 more
TL;DR: MBSR intervention achieved a prolonged reduction in psychosocial distress and improved health status of patients with type 2 diabetes and albuminuria and will be followed up further.